NEW YORK (GenomeWeb) – Next year, precision medicine company Ignyta will submit two applications for its lead therapeutic product entrectinib — one in ROS1-positive non-small cell lung cancer, and another for patients with any kind of solid tumor characterized by NTRK-fusions.

Ignyta not only plans to garner near concurrent review and approval entrectinib for the two indications, but also aims to introduce a multimarker NGS-based companion diagnostic on the market alongside the drug, which can identify patients who have these biomarkers and are most likely to respond.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.